IPO - MAINZ BIOMED N.V.

Form Type: F-1

Filing Date: 2025-05-14

Corporate Action: Ipo

Type: New

Accession Number: 000121390025042989

Filing Summary: Mainz Biomed N.V. filed a Registration Statement on Form F-1 with the SEC on May 14, 2025, indicating its intention to offer up to 2,448,980 ordinary units. Each unit will consist of one ordinary share, along with Class A and Class B warrants for purchasing additional ordinary shares. Also, up to 2,488,980 pre-funded units are being offered, designed to appease buyers whose ownership would exceed 4.99% post-offering. The offering is structured as a 'best efforts' basis, and no market listing for the offered securities is intended. The company, established under Dutch law, focuses on developing in-vitro diagnostic tests for early cancer detection, including its flagship product ColoAlert for colorectal cancer screening. A recent acquisition of licensing rights to novel biomarkers signifies a strategic extension of its product portfolio targeting pancreatic cancer. The filing indicates acknowledgments of significant market opportunities in molecular diagnostics, anticipating growth in demand for colorectal cancer screenings along with potential developments influenced by recent regulatory changes. The public offering price for the securities remains undetermined, subject to final negotiations. Proceeds from securities sales will be available for immediate use, despite uncertainty regarding capital adequacy to meet business objectives, thereby reflecting investment risks associated with the offering.

Form Type: F-1/A

Filing Date: 2025-05-14

Corporate Action: Ipo

Type: Update

Accession Number: 000121390025043331

Filing Summary: Mainz Biomed N.V. has filed its Amendment No. 1 to Form F-1 for a public offering of up to 2,488,980 ordinary units consisting of one ordinary share along with Class A and Class B warrants. The offering is structured as a best-efforts participation with no minimum requirement for proceeds, indicating a possible risk for under-subscriptions. The ordinary shares are traded under the symbol MYNZ on Nasdaq, and the company emphasizes its mission to enhance disease diagnosis through advanced genetic diagnostic technologies. The document notes the company's recent developments, including an exclusive agreement for mRNA biomarkers from Liquid Bioscience, to further its product offerings in cancer diagnostics. A reverse stock split of 1:40 was implemented on December 3, 2024, which impacts all share and per share amounts solidified in this prospectus. The amendment is significant as it updates the SEC on the offering’s conditions and relevance, along with its emerging growth company status and expectations surrounding the offering price, which will be determined at the time of pricing.

Form Type: DRS

Filing Date: 2025-04-09

Corporate Action: Ipo

Type: New

Accession Number: 000121390025030364

Filing Summary: Mainz Biomed N.V. is filing a confidential Draft Registration Statement under the Jumpstart Our Business Startups Act to register the offering of Ordinary Units and Pre-Funded Units in connection with an initial public offering intended to take place as soon as the registration statement becomes effective. The Ordinary Units consist of an Ordinary Share and a Warrant to purchase an Ordinary Share, while the Pre-Funded Units consist of a Pre-Funded Warrant to purchase an Ordinary Share in lieu of an Ordinary Unit. The offering includes registration for additional ordinary shares underlying these warrants. The placement agent is Maxim Group LLC, operating on a 'best efforts' basis with no minimum offering amount required. The document outlines significant details regarding underwriting, commission fees, and risks associated with the investment, emphasizing the offerings will promote the company’s diagnostic technologies for early cancer detection, specifically colorectal cancer, and will enhance financial growth based on recent developments such as acquiring new biomarkers and research projects.

Form Type: CORRESP

Filing Date: 2024-12-11

Corporate Action: Ipo

Type: New

Accession Number: 000121390024107647

Filing Summary: Mainz Biomed N.V. has submitted a request for the acceleration of the effectiveness of their Registration Statement on Form F-1, file number 333-282993. The company requests that the Registration Statement be made effective as of 5:00 pm Eastern Time on December 12, 2024. This request indicates the company's acknowledgment of its responsibilities under the Securities Act related to the pending public offering of securities. The company has requested to be notified of the effectiveness via a phone call to their counsel at Ortoli Rosenstadt LLP.